14 August 2024 - A new targeted cancer treatment, given in combination with a standard chemotherapy, for adults with stomach (gastric) or gastro-oesophageal junction cancer has today been approved by the MHRA.

Zolbetuximab has been studied in two main Phase 3 clinical trials – SPOTLIGHT and GLOW.

Read UK Government press release